Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rivastigmine 1.5 MG Oral Capsule

Known as: rivastigmine 1.5 MG (as rivastigmine tartrate 2.4 MG) Oral Capsule, RIVASTIGMINE TARTRATE 1.5 mg ORAL CAPSULE [Rivastigmine Tartrate], RIVASTIGMINE TARTRATE 1.5MG CAP,UD 
 
National Institutes of Health

Related topics

Related topics

28 relations
1-ButanolAlzheimer's DiseaseAmmoniaCarbamates
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Novel Benzene-Based Carbamates for AChE/BChE Inhibition: Synthesis and Ligand/Structure-Oriented SAR Study
A series of new benzene-based derivatives was designed, synthesized and comprehensively characterized. All of the tested… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 3
2013
2013
Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients
Background: Cognitive decline has been recognised as a frequent symptom in multiple sclerosis (MS). Cholinesterase inhibitors… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2010
2010
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
OBJECTIVES Since January 2008 in The Netherlands, two cholinesterase inhibitors, oral galantamine and rivastigmine transdermal… Expand
2010
2010
Galantamine of rivastigmine pleister. Een beschrijvend onderzoek op een geheugenpolikliniek in Nederland
SamenvattingDoel van onderzoek In Nederland zijn vanaf januari 2008 twee eenmaaldaags toe te dienen cholinesteraseremmers… Expand
2007
2007
No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats
Purpose[123I]FP-CIT SPECT is a valuable diagnostic tool to discriminate Lewy body dementia from Alzheimer’s dementia. To date… Expand
  • figure 1
2003
2003
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients
Summary. Centrally acting cholinesterase inhibitors (ChEIs) improve cognitive functions in Alzheimer's disease (AD) and other… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
2003
2003
PNM24 RIVASTIGMINE IS ASSOCIATED WITH SIGNIFICANTLY LESS CAREGIVER BURDEN THAN DONEPEZIL OR GALANTAMINE
 
2001
2001
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Centrally acting cholinesterase inhibitors (ChEls) improve cognitive functions in Alzheimer's disease (AD) and other forms of… Expand
2001
2001
Novartis provides guidelines for reinitiating rivastigmine therapy
  • 2001
    • Corpus ID: 195121149
 
2001
2001
Novartis provides guidelines for reinitiating rivastigmine therapy
  • 2001
    • Corpus ID: 195150540
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE